Top-News
Dienstag,
29.06.2021 17:10
von
PR Newswire
| Aufrufe: 55
First Photon Treatment Using Raystation in India by Mahatma Gandhi Cancer Hospital
Zeitungsständer (Symbolbild).
© AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images
PR Newswire
STOCKHOLM, June 29, 2021
STOCKHOLM, June 29, 2021 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces that RayStation®* now is in clinical use at Mahatma Gandhi Cancer Hospital & Research Institute (MGCH & RI), in Visakhapatnam, India making this the first photon treatment using Raystation in the country.
MGCH & RI is a renowned center of excellence for comprehensive cancer care and prevention, providing a broad spectrum of treatment modalities and facilities. MGCH & RI chose RayStation for innovative features such as adaptive workflow and fallback planning capabilities, which will provide the center's oncology specialists with innovative tools for the precise and effective treatment of different cancer types.
Dr. Murali Krishna Voonna, Managing Director at MGCH & RI, says: "Adding Raystation to the department will take radiation oncology to the next level, extend our treatment possibilities through ground-breaking features, high speed, advanced optimization and automaton."
Dr. Kanhu Charan Patro, Chief Radiation Oncologist at MGCH&RI, says: "I am amazed by RayStation's user experience and its capacity to work at the speed of thought. I am confident that RaySearch will help us to realize the system's full potential and maximize benefits to our patients through rapid planning with high precision."
Mr. A.C.Prabhu, Head of Medical Physics at MGCH&RI says: "Having RayStation in the department brings us great pride. I am confident that our daily work will be more efficient due to its intelligent combination of adaptive planning, automated planning and unrivaled computation speed."
Johan Löf, founder and CEO, RaySearch, says: "India is a rapidly growing market and there is a great need for flexible and efficient solutions to help clinics treat more patients. Several centers are already using RayStation for proton therapy, and we are proud to enable MGCH & RI to apply its advanced features to photon treatment."
The order was received in Q1 2021 and mainly generated revenues in Q1 2021, excluding support revenues.
About Mahatma Gandhi Cancer Hospital & Research Institute
MGCH & RI is a well-established center of excellence for comprehensive cancer care and prevention. As one of the leading cancer institutes in India, it provides seamless cancer care under one roof through services such as diagnostics, and state-of-the-art therapies including surgery, chemotherapy, radiotherapy, and symptom management to meet the needs of oncology patients. The hospital focuses on a patient-centered approach to improving quality of life and restoring hope.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system (TPS) and the oncology information system (OIS) RayCare*®. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand®, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.
More information: www.raysearchlabs.com
About RayStation
RayStation® is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
* Subject to regulatory clearance in some markets.
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59
peter.thysell@raysearchlabs.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Press release (PDF) | |
| https://news.cision.com/raysearch-laboratories/i/mgi,c2931221 | MGI |
View original content:https://www.prnewswire.com/news-releases/first-photon-treatment-using-raystation-in-india-by-mahatma-gandhi-cancer-hospital-301322203.html
SOURCE RaySearch Laboratories
Werbung
Mehr Nachrichten zur Raysearch Labs B Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
